Published in Cancer Weekly, August 4th, 2009
"The second quarter featured strong clinical data presentations with SGN-35, now named brentuximab vedotin, that continue to demonstrate a compelling objective response rate and tolerability profile in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma (ALCL)," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "In both of our phase I clinical trials, brentuximab vedotin achieved complete or partial responses in greater than...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.